About Valneva SE

Valneva SE, founded in 2013 through the merger of Intercell and Vivalis, has established itself as a leading specialty vaccine company developing innovative vaccines for infectious diseases. The company has built expertise in vaccine development and manufacturing for diseases with significant global health impact. VALN stock price reflects the company's vaccine development capabilities and exposure to global health trends.

Led by CEO Thomas Lingelbach, Valneva has advanced multiple vaccine programs through clinical development while building strategic partnerships and manufacturing capabilities. The management team combines vaccine development expertise with commercial capabilities to address global health needs. Leadership's strategic focus on addressing infectious diseases with significant unmet medical needs has been important for building a differentiated pipeline and influencing VALN stock price potential.

Valneva operates by developing and commercializing prophylactic vaccines for infectious diseases including Japanese encephalitis, cholera, and chikungunya virus, with additional programs targeting Lyme disease and other conditions. The company generates revenue from approved vaccines and development partnerships. With infectious diseases remaining significant global health challenges, growing travel and urbanization increasing disease exposure, and Valneva's established vaccine development expertise and regulatory capabilities, VALN offers investors exposure to specialty vaccine development with potential for meaningful global health impact and commercial success in underserved infectious disease markets.